Abstract
Multiple sclerosis (MS) is a disease of the central nervous system characterized by inflammation and demyelination resulting in clinical disability. The rodent MS model suggests that infiltration of monocytes and B cells contributes to disease pathogenesis. Here, we compared the migratory capacity of human monocytes and B cells from healthy control (HC) and relapsing-remitting MS (RRMS) subjects, with or without lipoic acid (LA) treatment. Basal migration of monocyte-enriched PBMCs from RRMS subjects is significantly higher than HC PBMCs. LA treatment significantly inhibits monocyte and B cell migration in both cohorts, and may thus be therapeutically effective for treatment of MS.
Original language | English (US) |
---|---|
Pages (from-to) | 24-27 |
Number of pages | 4 |
Journal | Journal of Neuroimmunology |
Volume | 315 |
DOIs | |
State | Published - Feb 15 2018 |
Keywords
- B cell
- Lipoic acid
- Migration
- Monocyte
- RRMS
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology